---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-264707"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:36:47.656447+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q3 revenue $160M (+15% YoY); sells 25% Crysvita royalty for $400M

## Summary
- Total revenue $160M (+15% YoY); Crysvita $112M, Dojolvi $24M, Evkeeza $17M.
- Net loss $180M ($1.81/share) vs $134M ($1.40) in Q3 2024; operating expense $331M.
- Received $400M from OMERS for additional 25% Crysvita royalty; repurchase option at $540M.
- FY2025 guidance reaffirmed: total rev $640-670M, Crysvita $460-480M, Dojolvi $90-100M.
- UX143 OI Phase 3 data expected year-end; DTX401 BLA submission on track for Q4 2025; UX111 BLA resubmission early 2026.

## SEC filing metadata
- accession: 0001193125-25-264707
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/0001193125-25-264707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/rare-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-264707
- JSON: https://secwatch.observer/filing/0001193125-25-264707.json
- Plain text: https://secwatch.observer/filing/0001193125-25-264707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.